(2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-nitrosomorpholine

(2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-nitrosomorpholine, also known as TRIM-17, is a synthetic compound that has been used in research to study its effects on the central nervous system. It has been found to have potential as a therapeutic agent for the treatment of various neurological disorders. TRIM-17 functions as a selective and potent inhibitor of the monoamine oxidase B (MAO-B) enzyme, which is responsible for the breakdown of dopamine and other neurotransmitters in the brain. By inhibiting MAO-B, TRIM-17 increases the levels of these neurotransmitters, leading to improved cognitive function and mood regulation. Chemically, TRIM-17 is a morpholine derivative that contains a nitroso group and a fluorinated phenyl ring. It is a chiral compound with two stereocenters, and the (2R,3S) configuration is the active enantiomer. The (R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy) group is a lipophilic moiety that enhances its ability to cross the blood-brain barrier and target the MAO-B enzyme. In conclusion, TRIM-17 is a promising compound for the treatment of neurological disorders, and its selective MAO-B inhibition mechanism makes it a potential alternative to traditional MAO inhibitors with fewer side effects.